生物制药公司Soligenix, Inc.近日宣布，其研发的SGX945用于治疗白塞病（Behçet's Disease）的孤儿药资格认定申请，已获得欧洲药品管理局（EMA）的积极评价。
这一重要进展意味着SGX945在针对这一罕见炎症性疾病的开发进程中迈出了关键一步。孤儿药资格认定旨在鼓励针对罕见疾病的药物研发，通常能为企业带来包括市场独占期在内的多项政策利好。
生物制药公司Soligenix, Inc.近日宣布，其研发的SGX945用于治疗白塞病（Behçet's Disease）的孤儿药资格认定申请，已获得欧洲药品管理局（EMA）的积极评价。
这一重要进展意味着SGX945在针对这一罕见炎症性疾病的开发进程中迈出了关键一步。孤儿药资格认定旨在鼓励针对罕见疾病的药物研发，通常能为企业带来包括市场独占期在内的多项政策利好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.